Hopes rise that Kevzara could help treat COVID-19 patients

30 March 2020

More details of Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) hotly-anticipated Phase II/III Kevzara (sarilumab) program targeting COVID-19 symptoms have been announced.

A second global trial has now been kicked off in multiple European countries, Russia and the USA. Sanofi will take responsibility for sites outside of the USA and Regeneron will take charge of the American side.

The firms have already teamed up with the Biomedical Advanced Research and Development Authority (BARDA) to investigate the potential of the therapy, a fully-human monoclonal antibody which inhibits the interleukin-6 (IL-6) pathway.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK